Real world study on efficacy and safety of surufatinib in advanced solid tumors evaluation
Abstract Surufatinib is a novel, China-developed small-molecule tyrosine kinase inhibitor that demonstrates high selectivity for VEGFR, FGFR1, and CSF1R. Surufatinib has been approved for the treatment of neuroendcrine tumors, including pancreatic neuroendocrine tumors (PNEN) and non-pancreatic neur...
Sábháilte in:
| Príomhchruthaitheoirí: | , , , , , , |
|---|---|
| Formáid: | Artigo |
| Teanga: | Inglês |
| Foilsithe / Cruthaithe: |
Nature Portfolio
2025-05-01
|
| Sraith: | Scientific Reports |
| Ábhair: | |
| Rochtain ar líne: | https://doi.org/10.1038/s41598-025-00974-8 |
| Clibeanna: |
Níl clibeanna ann, Bí ar an gcéad duine le clib a chur leis an taifead seo!
|